|Awarded On||August 21, 2019|
|Title||Alleviating SN-38-induced late-onset diarrhea by preserving local UGTs in the colon|
|Award Mechanism||High Impact/High Risk|
|Institution/Organization||Texas Southern University|
|Principal Investigator/Program Director||Song Gao|
|Cancer Sites||Breast, Colorectal, Pancreas|
*Pending contract negotiation
Chemotherapy-induced diarrhea is a common side effect but is an understudied area in cancer management. This problem is especially significant with irinotecan, a prodrug of SN-38 used to treat metastatic colon cancer as well as other types of cancers (e.g., pancreatic cancer). It is reported that more than 80% of patients treated with irinotecan experienced diarrhea, with up to 40% of severe late-onset diarrhea. The overall goal of this project is to develop diarrheal biomarkers and develop preventive agents against irinotecan-induced diarrhea. We will perform a series of experiments using both in vitro and in vivo models to determine the feasibility of developing a probe for diarrhea predic...